查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1484941

2024 年披衣菌感染披衣菌 (CT) 和淋病奈瑟菌 (NG) 检测全球市场报告

Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Global Market Report 2024
出版日期: | 出版商: The Business Research Company | 英文 175 Pages | 商品交期: 2-10个工作天内

价格
简介目录

披衣菌感染衣原体（CT）和淋病奈瑟菌（NG）检测市场规模预计在未来几年将快速成长。 2028年，将以11.0%的复合年增长率成长至30亿美元。预计未来的成长是由于远端医疗和远端医疗服务的使用增加、个人化医疗方法的采用、就地检验的扩大以及人口健康管理策略的实施。在此期间预计的主要趋势包括扩大快速就地检验能力、引入个人化检测方法、开发多疾病检测平台以及扩大以地区为基础的检测和推广计划。

性行为感染（STI）的日益普及预计将在短期内推动披衣菌感染衣原体（CT）和淋病（NG）检测市场的扩张。性行为感染是透过性接触传播的细菌、病毒和寄生虫感染疾病，由于性教育不足、性活动活性化、社会耻辱和接触障碍等因素，性传染感染呈上升趋势。 CT和NG检测在性传染感染的检测和管理中发挥重要作用，有助于早期诊断、治疗和感染预防。例如，根据世界卫生组织（WHO）2023年7月报告，全球每天有超过100万人新增感染性传染感染，每年新增感染者达3.74亿，占估计的四分之一。性传染感染。因此，性行为感染的流行凸显了 CTNG 检测市场的成长轨迹。

披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场的主要参与者正在优先考虑开拓创新的检测解决方案，以满足对抗性传播感染的准确且可扩展的检测方法日益增长的需求。 BD COR MX/PX 系统就是这类解决方案之一，它是一种高通量感染疾病分子诊断平台。这种复杂的测试设备旨在快速分析大量检体中的感染疾病。 BD COR MX/PX 系统由 Becton Dickinson 于 2022 年 5 月推出，简化了实验室处理大量传染病检查（包括 CT 和 NG 检测）的工作流程。该平台使用机器人技术和软体演算法来自动化整个测试过程，从而可能提高效率并减少测试结果等待时间。显着的特点包括自动化、高通量能力、双 DNA 靶向以及模组化和可扩展的设计。

目录

第一章执行摘要

第二章 市场特点

第三章 市场趋势与策略

第四章宏观经济情景

  • 高通膨对市场的影响
  • 乌克兰与俄罗斯战争对市场的影响
  • COVID-19 对市场的影响

第五章世界市场规模与成长

  • 全球披衣菌感染衣原体（CT）和淋病奈瑟菌（NG）检测市场：驱动因素和限制因素
    • 市场驱动因素
    • 市场限制因素
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场表现：规模和成长，2018-2023 年
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场预测：规模和成长，2023-2028 年，2033F

第六章 市场细分

  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场：按检测类型分類的实际和预测，2018-2023、2023-2028F、2033F
  • 实验室
  • 就地检验
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场：按产品分類的表现和预测，2018-2023、2023-2028F、2033F
  • 检测方法和套件
  • 设备或分析设备
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场：按技术分類的表现和预测，2018-2023、2023-2028F、2033F
  • 恒温核酸增幅技术
  • 聚合酵素链锁反应
  • 免疫诊断
  • 其他技术
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场：最终用户的表现和预测，2018-2023、2023-2028F、2033F
  • 诊断实验室
  • 医院和诊所
  • 其他最终用户

第 7 章 区域/国家分析

  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场：按地区分類的表现和预测，2018-2023、2023-2028F、2033F
  • 全球披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场：按国家/地区分類的表现和预测，2018-2023、2023-2028F、2033F

第八章亚太市场

第九章 中国市场

第十章 印度市场

第十一章 日本市场

第十二章 澳洲市场

第十三章 印尼市场

第14章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章 德国市场

第十八章 法国市场

第十九章 义大利市场

第20章 西班牙市场

第21章 东欧市场

第22章 俄罗斯市场

第23章 北美市场

第24章美国市场

第25章加拿大市场

第26章 南美洲市场

第27章 巴西市场

第28章 中东市场

第29章 非洲市场

第三十章 竞争格局及公司概况

  • 披衣菌感染衣原体（CT）与淋病（NG）检测市场：竞争格局
  • 披衣菌感染衣原体 (CT) 和淋病奈瑟菌 (NG) 检测市场：公司简介
    • F. Hoffmann-La Roche AG
    • Thermo Fisher Scientific
    • Abbott Laboratories
    • Danaher Corporation
    • Merck KGaA

第31章 其他大型创新企业

  • Siemens Healthineers
  • Becton Dickinson and Company
  • Grifols SA
  • Hologic Inc.
  • PerkinElmer
  • bioMerieux
  • Sysmex Corporation
  • Bio-Rad Laboratories
  • QIAGEN
  • Quidel Corporation
  • DiaSorin
  • Cepheid
  • Seegene Inc.
  • Meridian Bioscience Inc.
  • Sekisui Diagnostics

第32章竞争基准化分析

第 33 章. 竞争对手仪表板

第三十四章 重大併购

第35章前瞻性与潜力分析

第36章附录

简介目录
Product Code: r17309

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) testing involves diagnosing sexually transmitted infections (STIs) caused by these bacteria in sexually active individuals, particularly those with multiple partners or engaging in unprotected sexual activity. These tests aim to identify the presence of CT and NG bacteria through various methods such as urine samples, genital area swabs, or blood tests.

The primary testing methods for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG) are laboratory testing and point-of-care testing. Laboratories are specialized facilities equipped with trained personnel and specialized equipment to conduct CT and NG testing on patient samples. This includes a range of products such as assays, kits, instruments, and analyzers utilizing various technologies such as isothermal nucleic acid amplification technology, polymerase chain reaction, immunodiagnostics, among others. End users of these laboratory services include diagnostic laboratories, hospitals, clinics, and other healthcare facilities.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report is one of a series of new reports from The Business Research Company that provides chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market statistics, including chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry global market size, regional shares, competitors with a chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market share, detailed chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market segments, market trends and opportunities, and any further data you may need to thrive in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing industry. This chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size has grown rapidly in recent years. It will grow from $1.79 billion in 2023 to $1.98 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed during the historical period can be attributed to several factors, including the emergence of antibiotic resistance, heightened awareness campaigns and educational initiatives, as well as policy changes aimed at addressing the challenges posed by sexually transmitted infections (STIs) such as Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG).

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market size is expected to see rapid growth in the next few years. It will grow to $3.00 billion in 2028 at a compound annual growth rate (CAGR) of 11.0%. The forecasted growth in the upcoming period can be attributed to the increasing utilization of telemedicine and telehealth services, the adoption of personalized medicine approaches, the expansion of point-of-care testing, and the implementation of population health management strategies. Major trends anticipated in this period encompass the broadening of rapid point-of-care testing capabilities, the implementation of personalized testing approaches, the development of multi-disease testing platforms, and the expansion of community-based testing and outreach programs.

The escalating prevalence of sexually transmitted infections (STIs) is anticipated to drive the expansion of the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in the foreseeable future. STIs, resulting from bacterial, viral, or parasitic infections transmitted through sexual contact, are on the rise due to factors such as inadequate sex education, heightened sexual activity, societal stigma, and accessibility barriers. CT and NG testing plays a crucial role in the detection and management of STIs, facilitating early diagnosis, treatment, and prevention of transmission. For instance, as reported by the World Health Organization in July 2023, over 1 million new STIs are contracted daily worldwide, with an estimated 374 million new infections occurring annually, encompassing one in four treatable STIs. Consequently, the escalating prevalence of sexually transmitted infections underscores the growth trajectory of the CTNG testing market.

Key players in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are prioritizing the development of innovative testing solutions to address the growing need for accurate and scalable testing methods to combat STIs. One such solution is the BD COR MX/PX System, a high-throughput infectious disease molecular diagnostic platform. This sophisticated laboratory instrument is designed to rapidly analyze large numbers of samples for infectious agents. Launched by Becton Dickinson and Company in May 2022, the BD COR MX/PX System streamlines workflow in labs processing numerous infectious disease tests, including CT and NG testing. The platform automates the entire testing process using robotics and software algorithms, enhancing efficiency and potentially reducing wait times for test results. Notable features include automation, high-throughput capability, dual DNA targets, and a modular and scalable design.

In September 2021, F. Hoffmann-La Roche AG bolstered its molecular diagnostics portfolio by acquiring TIB Molbiol, a Germany-based biotechnology company, for an undisclosed sum. This strategic acquisition enhances Roche's capabilities in molecular diagnostics, particularly in infectious diseases, and broadens its range of tests for existing and emerging pathogens. TIB Molbiol's Lightmix Kit 480 HT CT/NG, a CT/NG testing solution, strengthens Roche's offerings in the STI testing segment, enabling the company to provide innovative diagnostic solutions and improve patient outcomes in the field of infectious diseases.

Major companies operating in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific, Abbott Laboratories, Danaher Corporation, Merck KGaA, Siemens Healthineers, Becton Dickinson and Company, Grifols SA, Hologic Inc., PerkinElmer, bioMerieux, Sysmex Corporation, Bio-Rad Laboratories, QIAGEN, Quidel Corporation, DiaSorin, Cepheid, Seegene Inc., Meridian Bioscience Inc., Sekisui Diagnostics, J. Mitra & Co. Pvt. Ltd., Atlas Medical, Hardy Diagnostics, Molbio Diagnostics Pvt. Ltd., NG Biotech

North America was the largest region in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market in 2023. The regions covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market includes revenues earned by entities by providing services such as diagnostic testing, sample collection, laboratory analysis, and confidential counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The chlamydia trachomatis (CT) and neisseria gonorrhoeae (NG) testing market also includes the sale of sample collection kits, control materials, laboratory equipment, and software solutions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

  • Including: 1) By Test Type: Laboratory; Point Of Care Testing
  • 2) By Product: Assays And Kits; Instruments Or Analyzers
  • 3) By Technology: Isothermal Nucleic Acid Amplification Technology; Polymerase Chain Reaction; Immunodiagnostics
  • 4) By End User: Diagnostic Laboratories; Hospitals And Clinics
  • Covering: F. Hoffmann-La Roche AG; Thermo Fisher Scientific; Abbott Laboratories; Danaher Corporation; Merck KGaA

Table of Contents

1. Executive Summary

2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Characteristics

3. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Trends And Strategies

4. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On The Market
  • 4.2. Ukraine-Russia War Impact On The Market
  • 4.3. COVID-19 Impact On The Market

5. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Size and Growth

  • 5.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Segmentation

  • 6.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Laboratory
  • Point Of Care Testing
  • 6.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Product, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Assays And Kits
  • Instruments Or Analyzers
  • 6.3. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Isothermal Nucleic Acid Amplification Technology
  • Polymerase Chain Reaction
  • Immunodiagnostics
  • Other Technologies
  • 6.4. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Diagnostic Laboratories
  • Hospitals And Clinics
  • Other End Users

7. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Regional And Country Analysis

  • 7.1. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 8.1. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 9.1. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 9.2. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 10.1. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 11.1. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 11.2. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 12.1. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 13.1. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 14.1. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 14.2. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 15.1. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 15.2. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 16.1. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 17.1. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 18.1. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 19.1. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 20.1. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 21.1. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 21.2. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 22.1. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 23.1. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 23.2. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 24.1. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 24.2. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 25.1. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 25.2. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 26.1. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 26.2. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 27.1. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 28.1. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 28.2. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

  • 29.1. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Overview
  • 29.2. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Test Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By Technology, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market, Segmentation By End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape And Company Profiles

  • 30.1. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Landscape
  • 30.2. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche AG
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Thermo Fisher Scientific
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Abbott Laboratories
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Danaher Corporation
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Merck KGaA
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Other Major And Innovative Companies

  • 31.1. Siemens Healthineers
  • 31.2. Becton Dickinson and Company
  • 31.3. Grifols SA
  • 31.4. Hologic Inc.
  • 31.5. PerkinElmer
  • 31.6. bioMerieux
  • 31.7. Sysmex Corporation
  • 31.8. Bio-Rad Laboratories
  • 31.9. QIAGEN
  • 31.10. Quidel Corporation
  • 31.11. DiaSorin
  • 31.12. Cepheid
  • 31.13. Seegene Inc.
  • 31.14. Meridian Bioscience Inc.
  • 31.15. Sekisui Diagnostics

32. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Benchmarking

33. Global Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market

35. Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market Future Outlook and Potential Analysis

  • 35.1 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Countries Offering Most New Opportunities
  • 35.2 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Segments Offering Most New Opportunities
  • 35.3 Chlamydia Trachomatis (CT) And Neisseria Gonorrhoeae (NG) Testing Market In 2028 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer